Law Ping-Yee, Erickson-Herbrandson Laurie J, Zha Qin Q, Solberg Jon, Chu Ji, Sarre Aili, Loh Horace H
Department of Pharmacology, Medical School, University of Minnesota, Minneapolis, Minnesota 55455-0217, USA. lawxx001@ umn.edu
J Biol Chem. 2005 Mar 25;280(12):11152-64. doi: 10.1074/jbc.M500171200. Epub 2005 Jan 18.
Homo- and heterodimerization of the opioid receptors with functional consequences were reported previously. However, the exact nature of these putative dimers has not been identified. In current studies, the nature of the heterodimers was investigated by producing the phenotypes of the 1:1 heterodimers formed between the constitutively expressed mu-opioid receptor (MOR) and the ponasterone A-induced expression of delta-opioid receptor (DOR) in EcR293 cells. By examining the trafficking of the cell surface-located MOR and DOR, we determined that these two receptors endocytosed independently. Using cell surface expression-deficient mutants of MOR and DOR, we observed that the corresponding wild types of these receptors could not rescue the cell surface expression of the mutants, whereas the antagonist naloxone could. Furthermore, studies with constitutive or agonist-induced receptor internalization also indicated that MOR and DOR endocytosed independently and could not "drag in" the corresponding wild types or endocytosis-deficient mutants. Additionally, the heterodimer phenotypes could be eliminated by the pretreatment of the EcR293 cells with pertussis toxin and could be modulated by the deletion of the RRITR sequence in the third intracellular loop that is involved in the receptor-G protein interaction and activation. These data suggest that MOR and DOR heterodimerize only at the cell surface and that the oligomers of opioid receptors and heterotrimeric G protein are the bases for the observed MOR-DOR heterodimer phenotypes.
此前有报道称阿片受体存在同源和异源二聚化现象及其功能后果。然而,这些假定二聚体的确切性质尚未明确。在当前研究中,通过在EcR293细胞中产生组成型表达的μ-阿片受体(MOR)与经蜕皮甾酮A诱导表达的δ-阿片受体(DOR)之间形成的1:1异源二聚体的表型,对异源二聚体的性质进行了研究。通过检测位于细胞表面的MOR和DOR的转运情况,我们确定这两种受体是独立内吞的。利用MOR和DOR的细胞表面表达缺陷型突变体,我们观察到这些受体的相应野生型无法挽救突变体的细胞表面表达,而拮抗剂纳洛酮则可以。此外,对组成型或激动剂诱导的受体内化的研究也表明,MOR和DOR是独立内吞的,并且无法“拖入”相应的野生型或内吞缺陷型突变体。此外,用百日咳毒素预处理EcR293细胞可消除异源二聚体表型,并且通过缺失参与受体-G蛋白相互作用和激活的第三细胞内环中的RRITR序列可对其进行调节。这些数据表明,MOR和DOR仅在细胞表面形成异源二聚体,并且阿片受体的寡聚体和异源三聚体G蛋白是观察到的MOR-DOR异源二聚体表型的基础。